131I therapy of toxic and non-toxic goiters.
For more than 50 years, 131I has been recognized as an effective tool for controlling thyroid hyperplasia and hyperactivity. The fixed dose administration is the simplest method with doses of 111-370 MBq (3 to 10 mCi) 131I being administered. More sophisticated methods aiming to deliver a well-defined amount of 131I per gram of thyroid tissue are handicapped by problems related to the evaluation of the goiter size and the prediction of the sensitivity of thyroid cells to radiation. The use of 131I in nontoxic multinodular goiter is to be reserved for specific situations.
Beckers
C
C
Centre of Nuclear Medicine, University of Louvain Medical School, Brussels, Belgium. Beckers@mnuc.ucl.ac.be
D000236:Adenoma / Q000532:radiotherapy*; D006042:Goiter / Q000150:complications / Q000532:radiotherapy*; D006044:Goiter, Nodular / Q000532:radiotherapy; D006801:Humans; D006980:Hyperthyroidism / Q000209:etiology; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D013971:Thyrotoxicosis / Q000209:etiology
D007457:Iodine Radioisotopes